This patent, valid until 2035, marks South Korea as the first country globally to approve these specific claims, reinforcing the growing significance of precision medicine in diabetes care, the company states.

“The granting of this patent marks another critical step forward in developing personalized treatments that address the underlying autoimmune mechanisms driving Type 1 Diabetes,” says Anton Lindqvist, Chief Scientific Officer of Diamyd Medical. “This strengthens the rational for integrating genetic screening into clinical diabetes care, enabling earlier diagnosis and intervention. Importantly, it is also critical for the expansion of our precision medicine portfolio.”

The approval further advances the foundation established in patients with HLA DR3-DQ2, a genetically distinct subgroup currently being targeted with the GAD-specific immunotherapy Diamyd in the Phase 3 DIAGNODE-3 trial. Similarly, research has shown that individuals with autoimmune diabetes who have the DR4-DQ8 genetic profile may be particularly responsive to treatment with insulin-specific immunotherapy. Up to 90% of Type 1 Diabetes patients carry at least one of these markers, both of which are strongly linked to the disease.

Source: Diamyd Medical